Keyword: Starboard Value

Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.

Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $74 billion Celgene deal. And an activist may be joining that list.

It was nearly two years ago that activist investors began urging Perrigo to hive off its specialty pharma unit. Now, it’s finally happening.

Last October, Depomed switched up its board to appease activist Starboard Value. But Starboard didn’t stop there, and now Depmed has a new CEO.

Floundering Perrigo’s CFO is hitting the road—along with hundreds of other employees, who didn’t have quite as much say in the matter.

Perrigo and its activist investor have come to an agreement, and it’s one that’ll overhaul the company’s board.

Depomed and activist investor Starboard Value have reached a settlement, putting an end to a months-long proxy fight. But what's next for the California drugmaker?